Gaudium IVF Reports Financial Results for Q4FY26 and FY26

Gaudium IVF Reports Financial Results for Q4FY26 and FY26​

Gaudium IVF and Women Health Limited, a prominent fertility and women's healthcare platform in India, announced its Audited Financial Results for the quarter and financial year ending March 31, 2026. The company reported significant growth across key financial metrics for both the fourth quarter and the full fiscal year.

Consolidated Financial Highlights​

The company's performance is outlined in the following table, reporting figures in X Crore:


*Note: PAT represents Profit After Tax from continuing operations.

Quarterly and Annual Performance Deep Dive​

Gaudium IVF reported that Q4 FY26 revenue from operations stood at 30.35 Cr, showing a year-over-year (YoY) growth of 12.74% compared to 26.92 Cr recorded in Q4 FY25. For the full fiscal year FY26, revenue reached 104.35 Cr, marking a substantial growth of 47.56% YoY from 70.72 Cr in FY25. This growth is attributed to higher patient volume at mature hubs and a strong clinical success rate.

In terms of profitability, Q4 FY26 EBITDA stood at 12.17 Cr, representing a 39.56% YoY increase from 8.72 Cr. The EBITDA margin for the quarter was 40.10%. For FY26, EBITDA totaled 37.70 Cr, a growth of 31.69% YoY from 28.63 Cr in FY25, with an EBITDA margin of 36.13%.

The profit after tax (PAT) saw significant growth. In Q4 FY26, PAT was 8.36 Cr, an increase of 29.46% YoY compared to 26.45 Cr. For the full year FY26, PAT stood at 24.48 Cr, reflecting a 27.69% YoY increase from 19.17 Cr in FY25, achieving a PAT margin of 23.47%.

Operational and Technological Milestones​

Operationally, the company maintained a network of 7 hubs and 28 spokes in FY26 and reported a strong clinical pregnancy success rate of 58% on the first IVF attempt.

A key development in the industry was reported in April 2026, when Gaudium IVF became the first IVF chain in India to integrate AI-led embryology into routine clinical practice. This was achieved through a partnership with UK-headquartered IVF 2.0, deploying the SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant) platforms.

Company Commentary and Future Outlook​

Dr. Manika Khanna, Chairperson and Managing Director of Gaudium IVF and Women Health Limited, noted that FY26 was a defining year as the company transitioned into a listed, institutional, and scalable fertility platform. She highlighted that Q4 performance was supported by steady patient volumes and continued cost discipline, which contributed to the growth in revenue, EBITDA, and PAT for both the quarter and the year.

Dr. Khanna emphasized that IVF treatment remains the core revenue driver, anchored by the 58% plus clinical success rate in the first attempt. The company's 15-bed Hospital facility at Janakpuri provides a continuum of care, spanning from fertility treatment to delivery and post-natal care.

Looking ahead, the focus remains on execution and expansion. Of the 19 new IVF hubs planned under the IPO use-of-proceeds, three hubs are expected to become operational soon, with a total of 10 expected in FY27. The plan includes 8 hubs in FY28 and 1 hub in FY29. This expansion aims to deepen presence in Tier-II markets while reinforcing existing metro hubs. Coupled with technological advancements like the AI-led embryology platforms, the company is positioned for responsible growth in the underpenetrated Indian fertility market with a debt-light balance sheet post-IPO.

About the Company​

Founded in 2009, Gaudium IVF and Women Health Limited is a leading fertility and women's healthcare provider in India. It offers advanced reproductive solutions and comprehensive care to women and couples across Delhi, Mumbai, Bangalore, Patna, Ludhiana, and Srinagar. Services provided include IVF, ICSI, IUI, fertility preservation, advanced genetic testing, high-risk pregnancy care, and minimally invasive gynecological procedures, all supported by integrated pregnancy care and 24/7 patient services. The company combines global expertise with state-of-the-art technology and personalized treatment protocols.

GAUDIUMIVF Stock Price Movement​

On Wednesday, GAUDIUMIVF shares slipped by 2.00% to settle at ₹116.79. The equity finished considerably lower than its previous day's close of ₹119.17.